Nuwellis, Inc. 8-K

What Happened

• On March 17, 2026, Nuwellis, Inc. announced the closing of its previously announced acquisition of Rendiatech, Inc. Rendiatech is an Israeli-based developer of automated kidney function monitoring technology intended to support clinical decision‑making in critically ill patients. The announcement was made in a Form 8-K under Item 8.01 (Other Events).

Key Details

• Date of filing/announcement: March 17, 2026.
• Target: Rendiatech, Inc., an Israeli developer of automated kidney function monitoring technology.
• Nature of deal: Closing of a previously announced acquisition (Form 8-K Item 8.01).
• Financial terms or purchase price: Not disclosed in the 8-K.

Why It Matters

• The acquisition adds automated kidney‑monitoring technology to Nuwellis’s portfolio, which could broaden its clinical offerings and support development or commercialization efforts in critical‑care nephrology.
• For investors, the immediate material impact (costs, revenue contribution, or timing of product commercialization) is not provided; watch for future SEC filings or company statements for integration plans, financial details, and potential clinical or regulatory milestones.